INTERNATIONAL MYELOMA SOCIETY

22nd International Myeloma Society Annual Meeting

 

September 17-20, 2025 Toronto
Close
N. Poster
Poster title
Applicant name
Status
  1-NSP The use of a BCMA-directed bispecific antibody to treat relapsed myeloma in a liver transplant patient receiving continuous T-cell immunosuppression and concurrent hemodialysis Kevin Brigle Received Received
  2-PA Safety and Efficacy of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Study Doris Hansen Received Received
  2-NSP Expanding Access to Bispecific Antibodies for Multiple Myeloma: A Multidisciplinary Model to Bridge Academic and Community Care Mary Steinbach Received Received
  3-NSP Establishing barriers and enablers to nurse-enabled, subcutaneous therapy self-administration programs for myeloma patients - Description of an implementation science study design Hayley Beer Received Received
  4-NSP Enhancing Patient Education and Support in Multiple Myeloma: A Toolkit-Based Nursing Intervention Tiffany DeHemmer Received Received
  5-PA The Role of Trogocytosis in BCMA CAR T Cell Therapy with Gamma-Secretase Inhbition Pinar Ataca Atilla Received Received
  6-PA Comparative Effectiveness of Teclistamab vs Real-World Physician´s Choice of carfilzomib-and/or pomalidomide-based regimens in LocoMMotion and MoMMent in TCE RRMM Karla Sanchez Received Received
  9-NSP Characterising Critical Disease Burdens: Integration of Primary Care Data and Real-Time Patient Monitoring to Transform Multiple Myeloma Care in the UK Andrea Preston Received Received
  10-NSP Evaluating a Hybrid Approach to Oncology Pharmacy: A Comparison of Service Delivery Models for Immunomodulatory Drug Management Hayley Underhill Received Received
  11-NSP Clonal Hematopoiesis in Multiple Myeloma: Current Implications and Future Directions Samuel Shewan Received Received
  14-PA Outpatient Step-Up Dosing of Teclistamab (TEC): An Implementation Process Shifting from the Academic Inpatient (IP) to Community Outpatient (OP) Setting Christine Chen Received Received
  17-NSP The power of partnership: supporting patient adherence to treatment through a unique collaboration of healthcare professional and patient organisations Monica Morris Received Received
  20-NSP Myeloma Patient Outcome Scale (MyPOS): cross-cultural adaptation and evidence of validity for Brazilian population Walter Braga Received Received
  24-PA Teclistamab and Talquetamab in Relapse/Refractory Multiple Myeloma (RRMM) Patients with Severe Renal Insufficiency: Case Series Rebecca Tokarski Received Received
  25-PA Monitoring and Management of CMV and other Viral Reactivations with Bispecific Antibodies (BsAbs) for Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Alice Feast Received Received
  26-PA Evaluation of sequential Absolute Lymphocyte Count (ALC) in patients with relapsed multiple myeloma (RRMM) with Cranial Nerve Palsies (CNPs) post Ciltacabtagene-autoleucel (cilta-cel) Karla Feliciano Salva Received Received
  28-PA Development of anti-AL amyloidosis CAR Phagocyte Therapy Jing Fu Received Received
  34-PA One-time ex-vivo conditioning of CAR-T cells with a novel metabolic modulator Taro Hitosugi Received Received
  37-PA Real world accelerated step-up dosing of Teclistamab and Talquetamab in the outpatient setting is feasible and associated with low incidence of cytokine release syndrome. Phuong Dao Received Received
  42-PA Peak Absolute Lymphocyte Count as a Biomarker for CAR T-cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleuecel Eric Jurgens Received Received
  51-PA Initial results of a phase 2 study to evaluate elranatamab (elran) post-idecabtagene vicleucel (ide-cel) consolidation (EPIC) in patients with relapsed/refractory multiple myeloma (RRMM) Matthew Lei Received Received
  59-PA A Phase 2 Study Measuring MRD Negativity after Talquetamab and Teclistamab Consolidation in Sequence As Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients (TALTEC) Diana Loigom Received Received
  62-PA Serologic Immunity to Measles, Mumps, and Rubella in Multiple Myeloma Patients Following Cellular Therapy: A Descriptive Analysis Patrick Hagen Received Received
  71-PA Real-World Safety and Efficacy of BCMA Bispecific Antibodies in Relapsed and Refractory Light Chain Amyloidosis Sandy Mazzoni Received Received
  72-PA Optimizing CAR-T Therapy in Multiple Myeloma: Outpatient Reinfusion of Cesnicabtagene Autoleucel (ARI0002h) Beatriz Merchan Muñoz Received Received
  75-PA MACROPHAGE ACTIVATION SYNDROME-LIKE IN MULTIPLE MYELOMA PATIENTS TREATED WITH THE ACADEMIC BCMA-DIRECTED CAR-T ARI0002H: GENOMIC INSIGHTS AND CLINICAL IMPLICATIONS Carlos Fernandez de Larrea Received Received
  82-PA Real-world outcomes of patients with multiple myeloma who received BCMA-targeted bispecific antibodies in British-Columbia Andree-Anne Pelland Received Received
  84-PA Drivers of primary resistance to BCMA-targeted T cell redirected therapies in high tumor burden Kirsten Pfeffer Received Received
  85-PA TRAIL-CD28 Armoring Enhances anti-BCMA CAR-T Cell Function and Overcomes Resistance in Multiple Myeloma Mansour Poorebrahim Received Received
  87-PA Racial and ethnic differences in outcomes of multiple myeloma patients treated with Teclistamab Alicia Richards Received Received
  89-PA Debulking Chemotherapy Abrogates the Risk of Non-Response in Multiple Myeloma Patients with High Tumor Burden Receiving Teclistamab Rintu Sharma Received Received
  91-PA Outcomes of Radiation Therapy Integrated with T-cell Engaging Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma Heta Patel Received Received
  93-PA Outcomes of CAR-T Cell Therapy in patients with AL Amyloidosis Melinda Tan Received Received
  97-PA Prophylactic Dexamethasone (dex) with Outpatient Step-Up Dosing (SUD) of Bispecific Antibodies (BsAb) in Multiple Myeloma (MM) v. Standard of Care (SOC) Inpatient Observation Cindy Varga Received Received
  100-PA Efficacy of subsequent T Cell Engagers following BCMA CAR-T therapy in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis Nikhil Vojjala Received Received
  112-PA Navigating Myeloma: Behavioral and Emotional Outcomes from a Patient-Centered Navigation Resource Veronica Bohorquez Received Received
  113-PA Time Constraints and Treatment Decisions: How Time Allowed for Decision Making Affects Patient Experience in Relapsed Refractory Multiple Myeloma Jorge Arturo Hurtado Martinez Received Received
  116-PA Progression patterns by positron emission tomography (PET) for relapsed / refractory Multiple Myeloma (RRMM) after CAR T cell therapy: Potential role for radiotherapy (RT)? Alexandra Dreyfuss Received Received
  117-PA Optimisation of patient-reported outcome measurement (PROMs) for patients with haematological cancer receiving CAR-T and bispecific antibodies: multi-stakeholder perspectives Kate Morgan Received Received
  119-PA When ICAN(S) Becomes ICANT: Clinician and Staff Perspectives on In-Hospital Neurotoxicity Grading Grace Ferri Received Received
  124-PA Evaluating the Most Influential Factors in Decision-Making in Women and Men with Relapsed Multiple Myeloma Martha Paola Anchondo Commesse Received Received
  126-PA Post-Traumatic Growth, Flourishing, and Spiritual Practice Among Adults with Blood Cancer: A Patient-Reported Wellbeing Cross-Sectional Study Cheri Marmarosh Received Received
  127-PA Survey-based research into patient-physician communication and treatment decision-making preferences in newly diagnosed multiple myeloma Masaki Iino Received Received
  128-PA Measles Antibody IgG Levels in Treatment Exposed Patients with Multiple Myeloma Melanie Johnston Received Received
  131-PA Gender Disparities in Sexual Health Communication Among Patients with Multiple Myeloma: a HealthTree Patient Based Survey Study JAPNEET OBEROI Received Received
  133-PA Update of the EORTC Quality of Life Multiple Myeloma module (EORTC QLQ-MY20). Results from the Phase I-II EORTC prospective study Charalampia Kyriakou Received Received
  138-PA Health-Related Quality of Life in a "real-world" cohort of Chilean patients with Multiple Myeloma. Rolando Martínez Figueroa Received Received
  141-PA The Optimising Outcomes in Myeloma Patients with Frailty (OOMPF) Study Hannah Miller Received Received
  144-PA Whole Body Magnetic Resonance Imaging (WBMRI) for Response Evaluation in Patients with Multiple Myeloma Ioannis Ntanasis-Stathopoulos Received Received
  147-PA Nutritional status of adults with multiple myeloma and its association with disease progression and survival IOANNIS NTANASIS-STATHOPOULOS Received Received
  149-PA Daratumumab versus Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma – Quality of Life and Efficacy Results from a Randomized Investigator-initiated Trial Sridevi Rajeeve Received Received
  152-PA PRO-Guided Treatment Readiness for Daratumumab in Myeloma: Feasibility and Accuracy Tine Rosenberg Received Received
  153-PA Operationalising patient selection for outpatient transplant in multiple myeloma: Subjective versus objective measures. Steven Chun-Min Shih Received Received
  158-PA The HSCT-BIOME Study: double-blinded, randomized, placebo-controlled trial using orally-administered, lyophilized faecal microbiota transplantation to prevent HSCT-associated complications Angelina Yong Received Received
  159-PA Performance of Deauville Score and Total Lesion Glycolysis as Response Markers for Multiple Myeloma with Extramedullary Disease Saurabh Zanwar Received Received
  161-PA ASSESSING THE CLINICAL IMPLICATIONS AND PROGNOSTIC VALUE OF LIGHT-CHAIN N-GLYCOSYLATION IN 781 MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS Elena Alejo Received Received
  163-PA Characteristics of Long-Term Survivors in Multiple Myeloma: Exploring Factors for Cure After Extended Folow-Up Rafael Alonso Fernandez Received Received
  165-PA Testing and validating a mass spectrometry based algorithm for response assessment in myeloma Lauren Campbell Received Received
  167-PA Measurable residual disease (MRD) dynamics reveals a therapeutic vulnerability state for early immunotherapy interception in multiple myeloma (MM) Noelia Collado-Gisbert Received Received
  170-PA Whole Genome Sequencing of cell-free DNA for Assessment of Minimal Residual Disease in High-Risk Smoldering Multiple Myeloma Benjamin Diamond Received Received
  175-PA Comprehensive characterization and pharmacological targeting of stem-like side population compartment in multiple myeloma Dana Cholujova Received Received
  178-PA Integrating p53 Protein Expression with Mutation and Copy Number Status Enhances Risk Assessment in Myeloma Pei Lin Received Received
  182-PA Minimal Residual Disease Kinetics in Patients with Multiple Myeloma Receiving First Line Treatment and the Association with their Progression-Free Survival; A Retrospective Study of 323 patients Panagiotis Malandrakis Received Received
  184-PA Stem cell autograft minimal residual disease negativity predicts improved outcomes after autologous stem cell transplant for multiple myeloma Noriko Nishimura Received Received
  185-PA Towards the identification of novel circulating biomarkers associated with bone disease in multiple myeloma Ioannis Ntanasis-Stathopoulos Received Received
  187-PA Peripheral Blood Clonotypic Mass Spectrometry-Based MRD Stratification Identifies Patients at Increased Risk of Progression After Quadruplet Therapy in NDMM Anna Pula Received Received
  190-PA 3D telomere profiling of MRD in liquid biopsy as a predictive marker of disease stability or progression Yulia Shifrin Received Received
  192-PA Refining MRD surveillance in multiple myeloma: Predictive insights from ultrasensitive bone marrow analysis Paula Tabares Received Received
  193-PA ABSOLUTE LYMPHOCYTE COUNT (ALC) =1,000 IS A SURROGATE OF CAR-T CELL EXPANSION AND A READILY AVAILABLE BIOMARKER TO PREDICT OUTCOMES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) Luis-Esteban Tamariz-Amador Received Received
  197-PA Utilization and Preferences of MRD Testing for patients with Multiple Myeloma: Insights from a Survey of 251 North American Hematologists and/or Oncologists Bhrugu Yagnik Received Received
  199-PA Elevated Non-Clonal Bone Marrow Plasma Cell Fraction at Diagnosis Is Associated with Improved Outcomes in Multiple Myeloma Saurabh Zanwar Received Received
  204-PA Daratumumab-based quadruplet therapy in functional high-risk RRMM (fRRMM) patients promotes CD8 T cell activation and expansion in the immune microenvironment Chaitanya Acharya Received Received
  206-PA A novel clinical assay comprehensively characterizes myeloma genomes from bone marrow and peripheral blood Francois Aguet Received Received
  211-PA Cyclin D1 beyond the cell cycle: a new role in t(11;14) MM Linda Baughn Received Received
  212-PA Spatial transcriptomics in extramedullary multiple myeloma reveals an M2 macrophage prominent TME Nicholas Bingham Received Received
  222-PA Dissecting B cell landscape and receptor repertoire in Plasma Cell neoplasms at single cell resolution Filippo Viviani Received Received
  228-PA A Novel Hypoxia Gene Signature from the HOVON-65/GMMG-HD4 phase 3 study Prognostic of Survival and Associated with Immune Suppression in the Tumor Microenvironment Janine Van Elssen Received Received
  230-PA Exploration of tumor immune gene expression to stratify progression risk in newly diagnosed multiple myeloma patients from CoMMpass with 1q cytogenetic abnormality Steven Foltz Received Received
  233-PA AN INTEGRATED SPATIAL AND SINGLE-CELL MULTIOMICS PLATFORM FOR TRANSLATIONAL RESEARCH IN MULTIPLE MYELOMA Edmund Watson Received Received
  234-PA Integrating Microenvironment with Tumor Multi-Omic using Unsupervised Machine Learning to Model Heterogeneity Refines Multiple Myeloma Subtypes and Reveals Immune-Based Clusters with Prognostic Impact Habib Hamidi Received Received
  240-PA Integrative Genetic Profiling of Circulating Tumour DNA And Bone Marrow for Multiple Myeloma Prognostication Regina Kwarteng Received Received
  248-PA Charting Spatial Heterogeneity in Multiple Myeloma by using a minimally invasive cell-Free DNA Profiling Marina Martello Received Received
  265-PA Unravelling the effect of subclonal copy number variants on immune microenvironment and survival Parvathi Sudha Kanhangad Kakkanath Received Received
  266-PA Monosomy 13 and Deletion of 13q Predict Inferior Outcomes in Multiple Myeloma Patients Undergoing Upfront Autologous Transplant Oren Pasvolsky Received Received
  267-PA Tumor-immune microenvironment interaction drives the co-evolution of multiple myeloma and immune cells in a novel mouse model engineered with human immune system Phaik Ju Teoh Received Received
  270-PA Spatial Transcriptomics Profiling Reveals resistance mechanisms in Extramedullary Myeloma Plasmacytomas following CAR T-Cell Therapy Alessandro Lagana Received Received
  272-PA Dual roles of IRE1a inhibition in reversing mitochondrial ROS-induced CD8+ T cell senescence and exerting direct anti-tumor effects in multiple myeloma Yike Wan Received Received
  274-PA Retrospective analysis of molecular profile of plasma cell myeloma at diagnosis SUET WING WONG Received Received
  284-PA Quadruplet Therapy and ASCT in Multiple Myeloma: Does It Increase Toxicity? Melchor Eloy Francisco Ravelo Received Received
  285-PA Secondary clones identified by mass spectrometry in baseline samples remain stable or disappear early during monitoring in multiple myeloma patients Jill Pauli Received Received
  287-PA A new PIKfyve inhibitor shows subnanomolar potency in multiple myeloma Cecilia Bonolo de Campos Received Received
  288-PA Phase 2 Registrational Study of Anitocabtagene Autoleucel for Relapsed and/or Refractory Multiple Myeloma (RRMM): Updated Results from iMMagine-1 Rebecca Chan Received Received
  289-PA Enhanced expression of TAGLN2 predicts negative prognosis in multiple myeloma Mengping Chen Received Received
  291-PA Comparative Analysis of Motixafortide versus Plerixafor for Stem Cell Mobilization and Collection in Multiple Myeloma: A Single Center Real-World Experience Sara Close Received Received
  293-PA Anti-adhesion Properties of KTX-1001, a Selective NSD2/MMSET Inhibitor, Enhance Carfilzomib Sensitivity in Multiple Myeloma Devi Nandana Received Received
  296-PA Treatment patterns and outcomes in the second and third lines and after triple-class exposure: subanalysis of the Latin American Multiple Myeloma Registry Study (MYLACRE). Karla Sanchez Received Received
  297-PA Functional Evaluation of RHEB as a Lineage-Selective Dependency in Multiple Myeloma Using Integrated CRISPR, Epigenetic, and Expression Analyses Ryan Joseph Received Received
  298-PA Uncovering shared cancer-restricted cryptic antigens as T cell targets in Multiple Myeloma patients treated with Dendritic Cell/Myeloma fusion vaccine Dimitra Karagkouni Received Received
  299-PA A35, a novel small molecule kinase inhibitor, shows high efficacy in multiple myeloma and overcomes IMiDs resistance Josefine Krüger Received Received
  300-PA Autophagy disruption via PIKfyve inhibition strikingly upregulates cholesterol metabolism in multiple myeloma Daniel Lee Received Received
  305-PA Computer-assisted AI to detect myeloma cells Sabine Mai Received Received
  308-PA EFFICACY AND SAFETY OF DARATUMUMAB-BASED SCHEMES IN OVER80_YEARS NEWLY DIAGNOSED MULTIPLE MYELOMA(NDMM) Martín García Andrea Received Received
  309-PA SETD7 is a novel therapeutic target for multiple myeloma carrying t(11;14) Sae Matsuoka Received Received
  313-PA Novel therapeutic targets kappa myeloma antigen (KMA) and lambda myeloma antigen (LMA) are expressed on malignant plasma cells from patients with plasma cell dyscrasias but not on normal plasma cells Rosanne Dunn Received Received
  316-PA Ex vivo evaluation of BCL-2 family member dependencies in multiple myeloma: synergistic combinations and biomarkers of sensitivity and resistance Rafael Renatino Canevarolo Received Received
  319-PA Preclinical activity of pharmacological inhibitors targeting KRAS and pan-RAS in multiple myeloma Torsten Steinbrunn Received Received
  320-PA Unc-51 Like Kinase 3 (ULK3) is essential for autophagy and cell survival in multiple myeloma. Marilena Tauro Received Received
  321-PA Belantamab Mafodotin plus Lenalidomide/Dexamethasone in Newly Diagnosed Patients with Multiple Myeloma: Long-Term Efficacy and Safety Results from the Phase 1/2 BelaRd Study Panagiota Tzani Received Received
  331-PA Real World Outcomes in Cardiac AL Amyloidosis: A Decade of Experience at a Multidisciplinary Amyloidosis Center Diana Basali Received Received
  341-PA Primary Results from A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma Elizabeth Hill Received Received
  344-PA Treatment Paradigms and Outcomes for Light Chain Amyloidosis Associated with Waldenstrom´s Macroglobulinemia Sharan Jhaveri Received Received
  347-PA SECURE Study: Early findings suggest MGUS diagnosis does not increase psychological distress Elizabeth Knight Received Received
  348-PA Diagnostic patterns and outcomes of amyloidosis screening in a monoclonal gammopathy clinic: a single center study Swarup kumar Received Received
  349-PA EXENT QIP-MS Detection of Stable Monoclonal Light Chain Glycosylation Enables Risk-Stratified MGUS Monitoring Jemma Larham Received Received
  355-PA Real-world Impact of Anti-CD38 Monoclonal Antibodies and Hematopoietic Stem Cell Transplant in Primary Plasma Cell Leukemia (2021 IMWG Criteria): A Single-center Analysis Vincent Luong Received Received
  356-PA Light-Chain Smoldering Multiple Myeloma: Natural History and Risk Stratification Based on the iStopMM Definition Cecilie Maeng Received Received
  357-PA The natural history of Smoldering Multiple Myeloma (SMM): Evolution of incidence and progression risk from 2005 to 2022 in a nationwide Danish population-based cohort Cecilie Maeng Received Received
  360-PA The Significance of a MGUS Tumor Board: Updates After Three Years of Success Sandy Mazzoni Received Received
  364-PA Clinical outcomes of patients with MGUS and diabetes/obesity on GLP-1 receptor agonists: a real-world, propensity-matched study Ioannis Ntanasis-Stathopoulos Received Received
  368-PA Mesenchymal stromal cell senescence is associated with progression from MGUS to multiple myeloma Kate Vandyke Received Received
  371-PA Light Chain Amyloidosis: Clinical Features and Immune Microenvironment Characterization in Bone Marrow and Cardiac Tissue Chao-Hung Wei Received Received
  372-PA Real-World Outcomes and Treatment Patterns in AL-Amyloidosis (AL-A) in Austria: An Analysis from the Austrian Interdiscplinary Amyloidosis Registry (AIDA) Wolfgang Willenbacher Received Received
  373-PA Subcutaneous Daratumumab + Bortezomib, Cyclophosphamide, and Dexamethasone in Asian Patients with Newly Diagnosed Light-chain (AL) Amyloidosis: Subgroup Final Analysis of the Phase 3 ANDROMEDA Study David Wang Received Received
  374-PA MGUS Prevalence from a Large-Scale Community Study from Rural India (IMAGe-002B Study) Uday Yanamandra Received Received
  385-PA Prognostic Value of 1p Deletion in Newly Diagnosed Multiple Myeloma Patients: A Nationwide Multicenter Cohort Study by the Korean Multiple Myeloma Working Party (KMM2306) Hyungwoo Cho Received Received
  387-PA Importance of re-induction in patients with transplant eligible multiple myeloma refractory to frontline therapy. Daniela Di Francesco Received Received
  389-PA A Novel Deep-Learning Method for Uncovering Hidden Prognostic Patterns in Multiple Myeloma and Beyond​ Maximilian Ferle Received Received
  391-PA The novel high-risk multiple myeloma IMS/IMWG criteria identify previously overlooked newly-diagnosed patients with poor prognosis: validation and real-world application Ioannis Ntanasis-Stathopoulos Received Received
  395-PA Race, Lenalidomide Dosing, and Survival in Newly Diagnosed Transplantation-Ineligible Multiple Myeloma Patients Armand Ghazanfar Received Received
  396-PA Patient Characteristics, Healthcare Utilization and Costs in Multiple Myeloma by Treatment Class Exposure – A German Claims Data Study Katja Greth Received Received
  398-PA Overview of First-Line Treatment of Multiple Myeloma Patients from Two Hematology Centers in Slovakia – Data from the RMG Registry Juliana Holasová Received Received
  399-PA Survival Outcomes and Safety of High-Dose Melphalan with Autologous Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study. Reetu Jain Received Received
  403-PA Predictors of High-Risk and Ultra High-Risk Multiple Myeloma from the Australia & New Zealand Myeloma and Related Diseases Registry (MRDR). Melissa Ng Liet Hing Received Received
  405-PA Nuanced treatment decision for newly diagnosed multiple myeloma patients between 65-75 years old Ja Min Byun Received Received
  415-PA Definition of transplant ineligibility in newly diagnosed multiple myeloma: a systematic review Karun Neupane Received Received
  416-PA Optimizing Belantamab Mafodotin Doses for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma in the DREAMM-9 study Cecelia Nguyen Received Received
  417-PA Evaluating a Value-Based, Measurable Residual Disease (MRD) - Focused Clinical Pathway in Patients with Newly Diagnosed Multiple Myeloma C. Anthony Blau Received Received
  420-PA Real-World (RW) Outcomes of Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Front-Line Daratumumab (dara) Lenalidomide (len) and Dexamethasone (dex) (DRd) Ricardo Parrondo Received Received
  422-PA Frontline Bortezomib-Based Therapy and Autologous Hematopoietic Stem Cell Transplantation in Latin American Multiple Myeloma Patients: Insights from a Real-World Multinational Cohort Camila Peña Received Received
  424-PA Daratumumab(Dara) Lenalidomide(R) maintenance following Dara-Carfilzomib(K)R Dexamethasone with tandem transplant in high-risk newly diagnosed myeloma patients: update of the phase 2 study IFM 2018-04 Bénédicte PIRON Received Received
  425-PA Enhancing GAH Score to Optimize Tolerance to Quadruplet Therapies in Multiple Myeloma: A Subanalysis of the GEM2017FIT Trial Borja Puertas Martínez Received Received
  426-PA Geriatric Assessment in Hematology-Guided Selection for Quadruplet Therapy in Transplant-Ineligible Myeloma. A post hoc analysis from GEM2017FIT trial Borja Puertas Martínez Received Received
  427-PA OPTIMIZING THE ALCYONE TRIAL: EFFICACY OF DARATUMUMAB AND BORTEZOMIB MAINTENANCE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS POST DVMP INDUCTION, 2 YEAR ANALYSIS Borja Puertas Martínez Received Received
  432-PA Exploratory analyses of progression-free survival (PFS) with lenalidomide-bortezomib-dexamethasone (RVd) alone/RVdASCT by Duffy genotype in patients (pts) with newly diagnosed multiple myeloma (NDMM) Steve Hill Received Received
  435-PA Survival Impact of Anti-CD38-Based Quadruplet Regimens in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Network Meta-Analysis and Reconstructed Individual Patient Data Meta-Analysis João Tadeu Souto Filho Received Received
  436-PA A Network Meta-Analysis of Randomized Clinical Trials Comparing the Efficacy of Daratumumab Versus Isatuximab in the Treatment of Multiple Myeloma João Tadeu Souto Filho Received Received
  437-PA Real-World Evaluation of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) Induction Followed by Daratumumab and Lenalidomide (DR) Maintenance in Transplant-Eligible Multiple Myeloma João Tadeu Souto Filho Received Received
  438-PA Pan-Pacific Multiple Myeloma (MM) Working Group Guidelines and Recommendations for CD38 Monoclonal Antibody-based Quadruplet Therapy and Management in Clinical Practice for Newly Diagnosed MM Mark MacRae Received Received
  439-PA Model-based assessment of monthly isatuximab dosing performance in newly diagnosed multiple myeloma patients using IMROZ phase 3 data Mark MacRae Received Received
  444-PA Evaluation of haematopoietic second primary malignancies in multiple myeloma: a single centre Australian experience Stephanie Talam Received Received
  445-PA DKRD vs. DVRD Induction Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma Oren Pasvolsky Received Received
  446-PA DVRD Induction Followed by Autologous Hematopoietic Stem Cell Transplantation for Older Patients with Multiple Myeloma Oren Pasvolsky Received Received
  447-PA Outcomes of Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant Following VRD or KRD Induction Therapy Oren Pasvolsky Received Received
  451-PA Evaluating racial and ethnic disparities in progression assessment patterns in routine clinical practice among patients with Newly Diagnosed Multiple Myeloma Ruoyi (Jocelyn) Wang Received Received
  461-PA Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk cytogenetics abnormalities: A single-arm, multi-center, observational clinical study Yuping Zhong Received Received
  463-PA Poor outcomes in extramedullary multiple myeloma persist despite novel therapies Nicholas Bingham Received Received
  465-PA Factors Influencing CAR T-Cell vs. Bispecific Antibody Preferences in Relapsed/Refractory Multiple Myeloma Magaly Valeria Escobedo Cruz Received Received
  469-PA Updated Results From the Phase 3 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Safia Dale Received Received
  470-PA Analysis of infectious risk in the multiple myeloma patients treated with bispecific antibodies. Real world experience Inmaculada Fernández Received Received
  472-PA PomCyDex in Relapsed/Refractory Multiple Myeloma: Impact of Prior Refractoriness in a Real-World Setting Marta Hidalgo-Soto Received Received
  475-PA DREAMM-7 Study of Belantamab Mafodotin + Bortezomib + Dexamethasone vs Daratumumab + Vd in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy Safia Dale Received Received
  477-PA Validation of a Rule-Based Algorithm for Line-of-Therapy Assignment in Multiple Myeloma Using Simulated Data Jorge Arturo Hurtado Martinez Received Received
  487-PA Real-world evidence of melflufen plus dexamethasone in heavily pretreated relapsed/refractory multiple myeloma patients: efficacy and safety from a single-center experience. Katia Mancuso Received Received
  489-PA Isatuximab Subcutaneous (Isa SC) via On-Body Injector (OBI) or Manual Injection for Relapsed/Refractory Multiple Myeloma (RRMM): Patient Experience from the Phase 2 IZALCO Study Shanen Collins Received Received
  494-PA Outcomes in Second-Line Lenalidomide-Refractory Patients in the Phase 3 DREAMM-7 Study of Belantamab Mafodotin, Bortezomib (V), and Dexamethasone (d) vs Daratumumab-Vd in RRMM Michael Checkoway Received Received
  497-PA Real World Survival outcomes of relapsed and refractory multiple myeloma patients receiving second line therapy and beyond in Asia Kye Ling Wong Received Received
  499-PA A Network Meta-Analysis of Belantamab Mafodotin + Bortezomib + Dexamethasone vs Alternative Regimens in 2L+ Relapsed/Refractory Multiple Myeloma: Updated Efficacy Outcomes of DREAMM-7 Cecelia Nguyen Received Received
  500-PA Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment (Including Dialysis): Results From the Phase I DREAMM-12 Study Cecelia Nguyen Received Received
  501-PA Characteristics and outcomes of Multiple Myeloma patients with post-transplant relapse: A Latin American Real-World Cohort Study Camila Peña Received Received
  502-PA Characterization of Infections in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf)–Based Regimens From the DREAMM-7 and DREAMM-8 Trials Safia Dale Received Received
  505-PA Efficacy and Safety of Isatuximab Subcutaneous (SC) Plus Carfilzomib and Dexamethasone (Isa-Kd) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Results of the Phase 2 Study IZALCO Shanen Collins Received Received
  506-PA Isatuximab subcutaneous via an on-body injector plus pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: Subgroup analysis by prior lines of therapy from the Phase 3 IRAKLIA trial Shanen Collins Received Received
  507-PA Patient perspectives from the Phase 3 IRAKLIA study of isatuximab (Isa) subcutaneous (SC) via on-body injector (OBI) vs Isa intravenous (IV) in relapsed/refractory multiple myeloma (RRMM) Shanen Collins Received Received
  508-PA Infection rate profile of etentamig monotherapy in patients with relapsed/refractory multiple myeloma Clancy Gates Received Received
  509-PA Real-World Use and Effectiveness of Venetoclax in Combination with Carfilzomib Plus Dexamethasone in t(11;14)-positive Relapsed/Refractory Multiple Myeloma: A Single-Center Retrospective Study Maria Kotsopoulou Received Received
  510-PA Delayed or Salvage Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma Oren Pasvolsky Received Received
  513-PA Clinical Features and Management of GPRC5D related AE in Chinese Relapsed/Refractory Multiple Myeloma Patients Treated with Talquetamab: MonumenTAL-1 China Cohort Experience David Wang Received Received
  514-PA Real-world Treatment Patterns, Effectiveness, and Safety of Daratumumab-based Regimens in Chinese Patients with Multiple Myeloma: Final Analysis of the MMY4032 Study David Wang Received Received
  520-PA Efficacy and safety of low-frequency daratumumab in systemic light-chain amyloidosis Zhen Cai Received Received
  521-PA EVOLUTION OF AGE AND CAUSES OF DEATH IN PATIENTS WITH MULTIPLE MYELOMA IN THE ERA OF NOVEL AGENTS. Abel Rosado Rodriguez Received Received
  524-PA Iberdomide Maintenance after Autologous Hematopoietic Cell Transplant for Patients who Previously Received Lenalidomide Maintenance Natalia Tijaro Ovalle Received Received
  526-PA Patterns of Use of Free Light Chain Testing in Patients with Multiple Myeloma in Colombia Nohemi Caballero Received Received
  527-PA Population Pharmacokinetic Model-Based Melphalan Dosing with Siltuximab Interleukin-6 Blockade in Older Multiple Myeloma Patients Undergoing AHCT: Phase II Run-In Results Natalia Tijaro Ovalle Received Received
  528-PA Real-World Management of Relapsed/Refractory Multiple Myeloma Following Early Anti-CD38 Exposure Esther Ortega Vida Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
10:44
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

22nd International Myeloma Society Annual Meeting

 

September 17-20, 2025 Toronto
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 17/09/2025 TO 17/09/2025
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
Logo Cert